Health-related quality of life in Croatian general population and multiple myeloma patients assessed by the EORTC QLQ-C30 and EORTC QLQ-MY20 questionnaires by Ledinski Ficko, Sanja et al.
Radiology and Oncology  |  Ljubljana  |  Slovenia  |  www.radioloncol.com
Radiol Oncol 2019; 53(3): 337-347. doi: 10.2478/raon-2019-0047
337
research article
Health-related quality of life in Croatian 
general population and multiple myeloma 
patients assessed by the EORTC QLQ-C30 and 
EORTC QLQ-MY20 questionnaires
Sanja Ledinski Ficko1,2, Vlatko Pejsa3, Vesna Zadnik4
1 University of Applied Health Sciences, Department of Nursing, Zagreb, Croatia
2 University of Ljubljana, Interdisciplinary Doctoral Study of Biomedicine, Ljubljana, Slovenia
3 Clinical Hospital Dubrava, Institut of Hematology, Zagreb, Croatia
4 Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Ljubljana, Slovenia
Radiol Oncol 2019; 53(3): 337-347.
Received 23 July 2019 
Accepted 9 August 2019
Correspondence to: Assoc. Prof. Vesna Zadnik, M.D., Ph.D., Institute of Oncology Ljubljana, Epidemiology and Cancer Registry,  
Zaloška cesta 2, SI-1000 Ljubljana, Slovenia. Phone: + 386 1 5879 451; E-mail: vzadnik@onko-i.si
Disclosure: No potential conflicts of interest were disclosed.
Background. The impact of disease and treatment on the patient’s overall well-being and functioning is a topic of 
growing interest in clinical research and practice. The aim of this study is to obtain reference data on quality of life of 
Croatian general population. Further, we aim to assess the impact of the disease and its primary systemic treatment 
on their health related quality of life (HrQoL) in multiple myeloma (MM) patients.
Patients and methods. Participants for the first part of the study were randomly selected from adult Croatian 
population. In the clinical part of the study MM patients were included as prospectively diagnosed within two years 
in two major Croatian haematological centres. The EORTC QLQ-C30 in both trials and QLQ-MY20 in MM patients only 
were applied for HrQoL assessment. 
Results. Gender, age and place of residence have great impact on quality of life scores in Croatian population. 
The MM patients at the time of diagnosis have lower QLQ-C30 scores for global quality of life, functional and symp-
tom scale scores, as well as single items. The type of disease followed by the choice of therapy options are important 
HrQoL determinants.  
Conclusions. The norm values available now for Croatian population will help to interpret HrQoL for clinicians and aid 
in planning cancer care interventions. This study identified treatment effect consistent with those from other observa-
tional studies and provided new data on HrQoL across two different treatment choices for MM patients. 
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Croatian population
Introduction
Cancer incidence is increasing both in devel-
oped and developing countries. According to the 
Croatian Institute for Public Health, in Croatia can-
cer incidence has been steadily rising from 1990 on. 
In 2016, there were 23,650 newly diagnosed cancer 
cases, less than 1 percent are younger than 20 years 
at diagnoses. Among adult patients 3 to 4 percent 
are diagnosed before the age of 40.1 Statistic data 
of the International Agency for Research on Cancer 
show that the incidence of multiple myeloma 
(MM) in Croatia for men is 4.0 with mortality of 2.1 
in 100,000 citizens, and for women the incidence 
is 3.4 with mortality of 2.1 in 100,000 citizens. This 
means that every year we have 225–260 new MM 
cases in Croatia. MM is more frequent in males; the 
incidence increases with age.1 In 2016, there were 
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no case of MM before the age of 40 in Croatia, and 
most patients are aged 70 years or more at the time 
of diagnosis.1 Given the number of patients, there is 
a great need for assessing the health-related qual-
ity of life (HrQoL) to improve the care of oncology 
patients. Therefore, quality of life assessment is be-
coming more common in oncology.2 
Health is one of the most important variables 
affecting well-being.3 World Health Organisation 
defines quality of life as the individuals’ percep-
tion of their position in life in the context of the 
culture and value system in which they live and in 
relation to their goals, expectations, standards and 
concerns.4 The impact of disease and treatment on 
the patient’s overall well-being and functioning is 
a topic of growing interest in clinical research and 
practice.5 Indicators of quality of life can provide 
evidence that is based on comparable and stand-
ardized measures and that can be used to improve 
the health care system. Conducting studies using 
various health-related quality of life measures is 
a basis for improvement of health care delivery.6 
In the last decades, the measurement of health-
related quality of life has gained acceptance as a 
primary or secondary endpoint in cancer research 
worldwide.7
Evaluation of quality of life is conducted by 
using standardized questionnaires.8 European 
Organization for Research and Treatment of Cancer 
(EORTC) has purposed a development of an inte-
grated, modular approach for evaluating the qual-
ity of life of cancer patient. They have launched a 
core EORTC quality of life questionnaire for can-
cer patients that consists of 30 questions (EORTC 
QLQ-C30). The EORTC QLQ-C30 is one of the 
most widely used instrument for assessing health-
related quality of life in cancer patients9 and has 
been used so far in more than 3000 studies world-
wide. The core questionnaire is supplemented by 
disease-specific modules.10 So far disease specific 
modules were developed for 13 different malig-
nant conditions. The EORTC QLQ-MY20 is specific 
questionnaire adjusted for patients with multiple 
myeloma. The EORTC QLQ questionnaires have 
been translated and validated into 81 languages. 
The EORTC QLQ-C30 and EORTC QLQ-MY20 ex-
ist also in Croatian language.11,12 
The normative (reference) values of QLQ-C30 
questionnaire for general healthy population are 
already available for some countries, for example 
Germany5, the Netherlands13, Denmark7, Sweden14 
and Slovenia.15 Typically, they demonstrate the 
decrease of HrQoL on all levels with age in both 
sexes. On the contrary, some symptoms such as 
pain and fatigue increase with age. The population 
norms are applied in clinical practice as an aid to 
the clinical assessment of an individual patient and 
in research to assist in the overall interpretation of 
results from clinical studies of HrQoL.
The knowledge on HrQoL in MM patients is 
scarce. The findings of the recent European cohort 
study provide a better understanding on how to 
improve the treatment of patients with MM in or-
der to improve their QoL. The data indicated that 
there is a need for better management of the treat-
ment of fatigue and bone related symptoms since 
those are the strongest HrQoL predictors. The 
study also suggested that specific QoL aspects can 
be notably improved by treatment which targets 
specific symptoms.16 
The aim of this study is to obtain reference da-
ta on quality of life in a representative sample of 
Croatian general population older than 40 years, 
and obtaining data on quality of life in MM patients 
with the aid of EORTC QLQ-C30 and QLQ-MY20 
questionnaires. The norm values will help to inter-
pret health-related quality of life data for clinicians, 
and aid in planning interventions for symptoms in 
the early stages of the disease. In MM patients, we 
aim to assess the impact of the disease and its pri-
mary systemic treatment on their HrQoL.
Patients and methods
Population sample
The study was conducted in the second half of 
2016 and during 2017. For the initial part of our 
study, eligible respondents were adults, aged 
over 40 at the entry, residents of Croatia with no 
history of a malignant disease. A random sample 
of adult inhabitants in all six regions of Croatia: 
Dalmatia, Slavonia, Istria, Podravina, Zagreb 
region and Medimurje has been obtained. The 
EORTC QLQ-C30 questionnaire supplemented by 
a demographic inquiry was personally delivered to 
randomly selected individuals. The data collection 
was carried out by specially trained medical nurs-
es in health centres, homes for the elderly, in the 
street and in other highly frequented places. For 
any randomly chosen adult we firstly determined 
their age and health status, and, in the case of not 
having a malignant disease and being older than 
40, we continued with collecting the quality of life 
data. From the 362 initially contacted, 310 respond-
ents were included in our population sample. Of 
51 not included respondents, 35 had cancer, while 
16 of them chose not to participate for different 
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personal reasons. The Survey Monkey Sample Size 
Calculator17 was used to estimate that such a sam-
ple size is sufficient for our study to reach adequate 
power.
Multiple myeloma patient sample
In the second part of the study MM patients older 
than 40 were included. A prospective study was 
conducted in the second half of 2016, 2017 and the 
first half of 2018. EORTC QLQ-C30 and EORTC 
QLQ-MY20 questionnaires were filled in by re-
spondents before and three months after treatment 
with chemotherapy and stem cell transplantation 
in two major haematological centres in Croatia: 
Clinical Hospital Dubrava and Clinical Hospital 
Merkur. Questionnaires were distributed to the 
respondents during their stay in hospital, at the 
moment when transplantation or chemotherapy 
is determined as a therapeutic procedure. The sec-
ond evaluation was conducted three months after 
therapeutic procedures. The sample consisted of 
25 respondents before and after stem cell trans-
plantation and 26 respondents before and after 
chemotherapy, which corresponds to a similar 
Czech research which evaluated the quality of life 
among malignant lymphoma and MM patients un-
dergoing autologous stem cell transplantation.16 
Additional five people were invited to the study 
but they chose not to participate.
Questionnaires
In both samples we used the EORTC QLQ-C30 
questionnaire which contains 30 questions. The of-
ficial Croatian translation of the questionnaire was 
used in assessing individual HrQoL during previ-
ous week. Respondents were offered four response 
alternatives: 1 “not at all”, 2 “a little”, 3 “quite a 
bit” and 4 “very much”. In the last two questions 
the range was 1 to 7 in which 1 is “very poor” and 7 
is “excellent”. The EORTC QLQ-C30 questionnaire 
consists of a general health/quality of life scale, 
and five functional scales: physical functioning, 
role functioning, cognitive functioning, emotional 
functioning and social functioning, and 13 symp-
tom items. Functional scale includes cognitive, 
emotional, physical, role and social functioning 
dimension. Symptom scale includes fatigue, nau-
sea or vomiting and pain, and single items include 
loss of appetite, constipation, diarrhoea, dyspnoea, 
financial impact and sleep disturbance. For general 
quality of life and functional scale, higher scores 
mean better quality of life while higher scores for 
symptom scale and single items mean lower qual-
ity of life.18 In addition to EORTC QLQ-C30 all the 
participants also responded to a questionnaire on 
their demographic data including age, gender and 
place of residence.
The EORTC QLQ-MY20 is specific questionnaire 
adjusted for patients with multiple myeloma. The 
official Croatian translation of the questionnaire 
was used in assessing individual HrQoL during 
the previous week. It consists of functional scales 
which include future perspective and body image, 
and symptom scale which includes disease symp-
toms and side effects of treatment. Respondents 
were offered four response alternatives: 1 “not at 
all”, 2 “a little”, 3 “quite a bit” and 4 “very much”. 
The higher the number of an item means poorer 
functioning.18 
Internal consistency
Some dimensions are composed of more than one 
answer, and the others include only one categorical 
answer. Internal consistency of multiple answers 
within single dimension was proved by using the 
Cronbach alpha coefficient of reliability. The high 
value of the Cronbach alpha coefficients suggests 
a very high reliability. The coefficients were as fol-
lows: general health status/quality of life (0,87), 
physical functioning (0,84), role functioning (0,86), 
emotional functioning (0,87), cognitive functioning 
(0,70), social functioning (0,88), fatigue (0,83), nau-
sea/vomiting (0,69) and pain (0,81). In case of a lack 
of response to a question, the average of the other 
answers was used, but only if at least half of the 
questions were answered.19-21 
To investigate if there is a correlation between 
EORTC QLQ-C30 and QLQ-MY20 scores, Pearson 
correlation coefficient calculations were performed.
Statistical analysis 
Demographic characteristics were analysed as 
categorical variables and are represented in num-
bers and relative frequencies. Four age categories 
(40-49, 50-59, 60-69 and 70+) and six geographical 
regions were applied. The chi-square test was ap-
plied for determining the statistical significance of 
difference in demographical characteristics among 
groups of individuals in the sample. The answers, 
which were recorded in the EORTC QLQ-C30 and 
EORTC QLQ-MY20 were converted into dimen-
sions, which evaluate the quality of life associated 
with health. Dimensions are ranged from 0–100 
according to the EORTC scoring instructions.18 
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Dimensions are described by the arithmetic mean 
and standard deviation. As suggested by Nielsen 
et al.22 Mann-Whitney U test was used to compare 
the dimensions within two groups (gender, treat-
ment). Where there were more than two groups 
for comparison (age, region) we used the Kruskal-
Wallis test. For testing the statistical significance 
of the change in dimensions before and after treat-
ment Wilcoxon signed rank test was used. 
Furthermore, for the first time to the best of our 
knowledge, the QLQ-C30 summary score of the 
EORTC QLQ-C30 was calculated for the popula-
tion reference scores. QLQ-C30 summary score 
is a single higher-order model based on 27 of the 
30 items of the QLQ-C30, excluding global qual-
ity of life and financial difficulties proposed by 
Giesinger et al.23 In our study we investigated the 
ability of the QLQ-C30 summary score to distin-
guish between groups formed according to treat-
ment choice (chemotherapy, transplantation) and 
general population.
The values of p < 0.05 were evaluated as sta-
tistically significant. Statistical analysis was per-
formed using the 24.0 SPSS Inc., Chicago, IL, SAD 
software.
Compliance with ethical standards
The data collection, preparation, implementation 
and presentation were in accordance with legal 
requirements for protecting the confidentiality of 
personal information: in Croatia non-drug trials 
are reviewed by ethics committees at an institu-
tional level. Approval for the study was obtained 
from the Medical Ethics Committee of the Clinical 
Hospital Dubrava and Clinical Hospital Merkur 
(03/1-6234). All participants were fully informed 
about the aims of the study and provided written 
informed consent for participation in the study.
TABLE 1. Mean score (MS) and standard deviations (SD) for all EORTC QLQ-C30 dimensions and scales by age for general population
40–49 50–59 60–69 70 and older
p*
MS SD MS SD MS SD MS SD
Global health status/quality of life 69.1 18.6 71.1 20.7 67.4 19.9 56.9 23.9 .035
Physical functioning 86.2 12.9 83.9 16.9 81.8 21.7 61.2 30.2 .000
Role functioning 86.1 20.6 85.9 20.2 80.8 28.6 69.1 37.2 .128
Emotional functioning 71.9 22.4 78.2 19.7 78.6 19.7 66.7 26.4 .034
Cognitive functioning 80.6 21.7 85.7 17.8 85.6 17.4 80.8 26.3 .402
Social functioning 86.8 20.1 90.6 15.5 88.5 20.8 76.5 31.0 .049
Fatigue 33.7 20.8 28.0 22.7 29.5 22.8 43.8 29.2 .014
Nausea/vomiting 6.9 14.2 4.9 11.3 4.6 10.4 10.3 20.1 .276
Pain 25.8 24.3 23.3 24.5 24.1 27.8 40.2 32.3 .028
Dyspnoea 18.8 24.6 17.3 23.6 22.1 25.9 26.5 30.6 .362
Insomnia 24.4 28.7 26.3 30.2 30.7 30.5 41.2 37.7 .094
Appetite loss 6.9 15.2 5.3 13.7 8.2 15.6 24.5 34.1 .001
Constipation 8.2 18.0 8.3 19.2 13.8 21.9 14.7 28.7 .164
Diarrhoea 7.9 15.8 6.5 13.9 6.2 13.0 13.7 26.1 .595
Financial difficulties 7.6 17.7 7.4 17.7 14.4 26.9 22.5 33.6 .009
Summary score 83.1 12.5 85.8 12.2 82.9 15.0 72.6 23.7 .030
*p = Kruskal-Wallis test
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FIGURE 1. Summary score for EORTC QLQ-C30 in general population, initial testing 
and post-testing.
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Results
From the general population there were 310 ques-
tionnaires eligible for analysis; 68.4% women (212 
persons) and 31.6% men (98 persons). The largest 
number of the respondents were in the age range 
of 50–59 years, at 36.8% (114 persons). Most of the 
respondents were from the Zagreb region, at 33.9% 
(105 persons). Furthermore, 51 MM patients were 
included in the second part of the research. The 
largest number of the MM respondents were in the 
age range of 60–69 years, 20 patients. 25 of the re-
spondents were treated with chemotherapy while 
26 of the respondents underwent transplantation. 
Supplement table 1 shows how the groups differ in 
their demographic characteristics. 
Scale and item scores 
Results illustrate the transformed values of general 
quality of life, functional and symptom scales in 
the range 1–100. Table 1 shows the results for the 
EORTC QLQ-C30 for all scales, single items, as 
well as the summary score in general population 
according to age. In many dimensions there is a 
statistically significant difference in age in our sam-
ple. The scores for general health status are highest 
for the respondents aged 50–59 and lowest for the 
respondents who are 70 and older. Furthermore, 
there is also a statistically significant difference ac-
cording to age for physical functioning, emotional 
functioning and social functioning. The scores are 
significantly lower for respondents aged 70 and 
older. EORTC QLQ-C30 summary scores also in-
dicate that there is a statistically significant differ-
ence according to age, where scores are lower with 
increasing age.
Supplement Figure 1 shows mean scores of 
EORTC QLQ-C30 scores for all scales and items 
in general population according to age and gen-
der. Men reported better general quality of life, as 
well as better physical and emotional functioning. 
There is a statistically significant difference if we 
compare the results for symptom scale and single 
items for fatigue, pain, dyspnoea and insomnia by 
gender, where the ranges are higher for women. 
Men reported better functioning for all items on 
the symptom scale. If we compare the results for 
single items, women reported less constipation, 
diarrhoea and financial problems. Supplement 
Figure 2 shows EORTC QLQ-C30 summary score 
in Croatian general population according to age 
and gender. Supplement Table 2 shows results 
for the EORTC QLQ-C30 for all scales and sin-
gle items according to a place of residence. There 
is a statistically significant difference in general 
health status according to a place of residence; 
the scores are higher for respondents from Istria 
and Medimurje, and lowest for respondents from 
Dalmatia. Furthermore, there is a statistically sig-
nificant difference in physical functioning, role 
functioning, emotional functioning, cognitive func-
tioning and social functioning according to a place 
of residence; the scores are again the highest for 
respondents from Istria and Medimurje.
Table 2 presents the comparison between gen-
eral population and multiple myeloma patients 
for all EORTC QLQ-C30 dimensions. There is a 
statistically significant difference for global health 
status, physical functioning, physical functioning, 
role functioning, social functioning, fatigue, pain, 
appetite loss and financial difficulties. The values 
for global health status, physical functioning, role 
functioning and social functioning are higher in 
general population while values for fatigue, pain, 
appetite loss and financial difficulties are higher in 
MM patients.
There is a statistically significant difference in 
physical functioning, cognitive functioning, social 
TABLE 2. Mean score (MS) and standard deviation (SD) for all EORTC QLQ-C30 
dimensions and scales in general population and multiple myeloma (MM) patients 
at diagnosis at the time of setting the diagnosis
MM patients 
at diagnosis
General 
population 
MS SD MS SD P*
Global health status/ quality of life 58.9 19.4 68.2 20.6 .003
Physical functioning 63.0 26.2 81.7 20.1 .000
Role functioning 52.6 38.6 83.1 25.1 .000
Emotional functioning 75.8 21.7 75.1 21.6 .820
Cognitive functioning 82.0 22.0 83.5 20.1 .725
Social functioning 60.1 34.0 87.4 20.6 .000
Fatigue 41.0 24.3 31.9 23.4 .014
Nausea/vomiting 7.5 13.9 6.2 13.3 .346
Pain 38.2 33.4 26.1 26.5 .020
Dyspnoea 27.5 29.6 19.7 25.2 .078
Insomnia 31.4 32.9 28.3 30.9 .556
Appetite loss 21.6 34.5 8.5 18.7 .010
Constipation 13.7 25.9 10.1 20.8 .392
Diarrhoea 9.8 20.3 7.7 16.2 .712
Financial difficulties 39.2 36.9 10.6 22.6 .000
Summary score 72.9 17.8 83.0 14.8 .000
*p = Mann-Whitney test
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functioning, fatigue, pain, insomnia and financial 
difficulties in the measurements before and af-
ter chemotherapy where the results are worse in 
measurements after chemotherapy. Furthermore, 
there is statistically significant difference for global 
health status, role functioning, social functioning, 
nausea and vomiting, diarrhoea and financial dif-
ficulties in measurements after transplantation. For 
global health status in post-testing positive ranks 
in 15 cases were observed which means that they 
indicate better results. For role functioning posi-
tive ranks in 15 cases were observed while in so-
cial functioning positive ranks in 14 cases were 
observed which means that they indicated worse 
results. While for nausea and vomiting in 8 cases, 
constipation in 7 cases, diarrhoea in 7 cases and fi-
nancial difficulties in 12 cases negative ranks were 
observed which means that they indicate better re-
sults (Table 3).
When analysing QLQ-MY20 questionnaire, 
there is a statistically significant difference for body 
image and disease symptoms in measurements be-
fore and after chemotherapy. In post-testing nega-
tive ranks in 7 cases for body image were observed 
which means that they indicate better results. For 
disease symptoms in post-testing positive ranks in 
16 cases were observed which means that the values 
were higher in post-testing in accordance to initial 
TABLE 3. Mean score (MS) and standard deviation (SD) for all EORTC QLQ-C30 dimensions and scales in multiple myeloma (MM) patients before and 
after chemotherapy and transplantation
MM–before 
chemotherapy 
MM–after 
chemotherapy p*
MM–before
transplantation
MM–after 
transplantation p*
MS SD MS SD MS SD MS SD
Global health status/ quality of life 53.3 21.4 49.7 22.5 .283 64.4 15.7 74.7 18.0 .008
Physical functioning 53.9 26.3 38.9 21.3 .011 71.8 23.4 71.8 19.1 .955
Role functioning 50.7 39.8 46.7 31.9 .458 54.5 38.2 77.6 24.5 .009
Emotional functioning 73.3 27.6 78.0 21.9 .776 78.2 14.5 84.3 23.3 .107
Cognitive functioning 78.0 27.1 57.3 28.1 .007 86.0 14.9 91.0 14.3 .083
Social functioning 57.3 37.6 787 26.6 .007 62.8 30.7 78.0 26.1 .026
Fatigue 43.1 27.3 64.0 22.3 .001 39.1 21.5 40.2 24.6 .782
Nausea/vomiting 7.3 15.3 5.3 13.4 .603 7.7 12.7 0.0 0.0 .010
Pain 39.3 36.9 54.7 25.2 .039 37.2 30.3 31.4 28.0 .323
Dyspnoea 28.0 32.9 33.3 30.4 .590 26.9 26.7 17.9 23.5 .100
Insomnia 40.0 36.0 14.7 23.7 .010 23.1 27.9 20.5 31.4 .637
Appetite loss 28.0 38.1 21.3 35.8 .463 15.4 30.2 7.7 17.1 .286
Constipation 16.0 32.1 20.0 28.9 .564 11.5 18.7 1.3 6.5 .011
Diarrhoea 9.3 22.6 6.7 19.2 .414 10.3 18.3 1.3 6.5 .035
Financial diffuclities 41.3 41.1 14.7 28.9 .005 37.2 33.1 20.5 29.9 .018
Summary score 69.6 19.5 67.7 14.5 .181 76.0 15.7 83.3 9.7 .097
*p = Wilcoxon signed rank test
TABLE 4. Mean score (MS) and standard deviation (SD) for all QLQ-MY20 scales in multiple myeloma (MM) patients before and after chemotherapy 
and transplantation
MM–before 
chemotherapy 
MM–after 
chemotherapy p*
MM–before
transplantation
MM–after 
transplantation p*
MS SD MS SD MS SD MS SD
Future perspective 2.2 0.7 2.0 0.7 .285 2.2 0.7 1.8 0.7 .036
Body image 1.9 1.3 1.4 0.9 .023 1.4 0.6 1.4 0.6 1.00
Disease symptoms 1.9 0.6 2.2 0.6 .039 1.7 0.6 1.8 0.7 .571
Side effects of treatment 2.1 0.7 1.8 0.4 .361 1.9 0.6 1.5 0.3 .144
*p = Wilcoxon signed rank test
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testing. Furthermore, there is a statistically signifi-
cant difference for future perspective in measure-
ments before and after transplantation (Table 4).
We investigated the ability of the QLQ-C30 
summary score to distinguish between groups 
formed according to treatment choice (chemo-
therapy, transplantation) and general population 
status. Using the treatment choice as a variable, 
the QLQ-C30 summary score showed the chang-
es from the initial testing to post-testing. For MM 
patients on chemotherapy, results showed that 
in comparison to general population and trans-
planted patients, their functional scale was worse 
in the initial testing and it further deteriorated in 
post-testing. For transplanted patients the results 
showed worse results in comparison to general 
population but better when compared to patients 
on chemotherapy. In post-testing the results were 
improved. Three months after treatment the sum-
mary score was comparable to general population 
and significantly better when compared to patients 
on chemotherapy.
Correlation between EORTC QLQ-C30 
and QLQ-MY20 in MM patients before 
treatment 
The correlations between the EORTC QLQ-C30 di-
mensions and scales and 4 items of the QLQ-MY20 
before treatment are shown in Table 5 for patients 
on chemotherapy, and Table 6 for transplanted pa-
tients. The strongest positive correlation was found 
for pain (0.779) and disease symptoms, and strong-
est negative correlation for fatigue (-0.808) and 
physical functioning for patients on chemotherapy. 
Furthermore, for transplanted patients the strong-
est positive correlation was found for pain (0.707) 
and disease symptoms, and strongest negative cor-
relation for physical functioning (-0.710) and side 
effects of treatment. 
Discussion
Quality of life is now widely recognized as a cen-
tral outcome of many clinical trials.3 It is a multi-di-
mensional concept based on a holistic view of hu-
man well-being. It considers a number of domains 
of people’s lives and the interplay between these 
dimensions. The principal domains include: sub-
jective well-being, health, income and standard of 
living, relationship with family and friends, work 
and quality of jobs, sense of inclusion in one’s local 
community, and personal safety.24 
In this study we presented the reference data 
of the EORTC QLQ-C30 quality of life dimensions 
for the general Croatian population. This study 
begun with the aim of obtaining reference data of 
the EORTC QLQ-C30 quality of life dimension in a 
sample of Croatian adults older than 40 years who 
were not suffering from a malignant disease. In 
Croatia, there is around 30% of population younger 
than 40 years, however there are only around 4% of 
cancer patients that are diagnosed below this age.1 
The collected data are transformed into expected 
mean HRQL scores for distinctive demographic 
population groups.
Our results illustrate that mean scores vary with 
age, gender and place of residence. Men reported 
better general health status as well as physical and 
emotional functioning. On the symptom scale they 
reported less symptoms when compared to wom-
en. Women reported significantly higher scores for 
fatigue, pain, dyspnoea and insomnia. These find-
ings are similar to those of the Norwegian study, 
which was the first to be conducted in a general 
population. Their study also showed that men re-
ported fewer symptoms and better quality of life 
on all scales.25 Moreover, a study conducted in 
German general population showed that men re-
ported better quality of life on all scales and few-
er symptoms in comparison to women.5 The first 
study conducted on a South-eastern European 
population was in neighbouring Slovenia, also 
showed that men report better quality of life on 
the majority of specific scales and that they report 
fewer symptoms, but the results were mostly not 
statistically significant.15 
Our study also highlights that all scores dete-
riorated with age and older respondents reported 
more symptoms present. Scores were statistically 
higher for respondents 70 and more years old for 
physical, emotional and social functioning. The 
study conducted in the Norwegian population also 
showed that increasing age influences the scores; 
both QoL scales and all functional scales, except 
for emotional, showed a gradual decline in mean 
scores with increasing age for both sexes.25 The 
study conducted in Slovenia also showed that old-
er participants report more symptoms.15 For gener-
al health status the ranges are interestingly highest 
for the age group 50–59 in the Croatian population. 
The results indicate that place of residence 
has great impact on quality of life. Two of the ar-
eas in Croatia report better global functioning and 
less symptoms present. The ranges for physical, 
emotional, cognitive and social functioning are 
the highest for the respondents from Istria and 
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TABLE 5. Correlation between dimensions and scales in the EORTC QLQ-C30 and QLQ-MY20 (chemotherapy)
FP BI DS SET GHS PF RF EF CF SF F NV P D I AL C DIA FD
FP 1 .369 .330* .395* -.213 -.254 -.443 -.478 -.057 -.410 .086 .149 .322* .119 -.104 .309* .004 .017 .264
BI .369 1 .208 .586 -.135 -.155 -.333* -.428 -.101 -.396 131 .299* .164 -.044 .107    .186 -.074 .229 .270
DS .330* .208 1 .669 -.459 -.678 -.429 -.369 -.545 -.400 .642 .289* .779 .255 -.127 .512 .150 .274 .243
SET .395* .586 .669 1 -.277 -.513 -.462 -.579 -.577 -.568 .560 .599 .482 .116 .305 .644 -.121 .451 .469
GHS -.213 -.135 -.459 -.277 1 .427 .341* .503 .336* .468 -.399 -.205 -.332* -.283* .013 -.528 -.033 -.489 -.335*
PF -.254 -.155 -.678 -.513 .427 1 .588 .367 .524 .430 -.807 -.277 -.725 -.337* .165 -.389 -.156 -.136 -.147
RF -.443 -.333* -.429 -.462 .341* .588 1 .384 .359* .491 -.564 -.373 -.554 -.376 -.094 -.449 -.113 -.259 -.316*
EF -.478 -.428 -.369 -.579 .503 .367 .384 1 .329* .692 -.266 -.616 -.408 .115 .048 -.596 -.117 -.424 -.414
CF -.057 -.101 -.545 -.577 .336* .524 .359* .329* 1 .176 -.625 -.383 -.502 -.170 -.088 -.424 .043 -.349* -.262
SF -.410 -.396 -.400 -.568 .468 .430 .491 .692 .176 1 -.225 -.498 -.353* -.134 .007 -.589 .064 -.304* -.534
F .086 .131 .642 .560 -.399 -.807 -.564 -.266 -.625 -.225 1 .272 .717 .456 .066 .374 .127 .369 .119
NV .149 .299* .289* .599 -.205 -.277 -.373 -.616       -.383 -.498 .272 1 .227 -.139 .083 .605 .125 .361* .317*
P .322* .164 .779 .482 -.332* -.725 -.554 -.408 -.502 -.353* .717 .227 1 .350* -.178 .389 .161 .222 .182
D .119 -.044 .255 .116 -.283* -.337* -.376 .115 -.170 -.134 .456 -.139 .350* 1 .204 .078 -.187 .206 .160
I -.104 .107 -.127 .305 .013 .165 -.094 .048 -.088 .007 .066 .083 -.178 .204 1 .238 -.186 .271 .194
AL .309* .186 .512 .644 -.528 -.389 -.449 -.596 -.424 -.589 .374 .605 .389 .078 .238 1 .000 .329* .375
C .004 -.074 .150 -.121 -.033 -.156 -.113 -.117 .043 .064 .127 .125 .161 -.187 -.186 .000 1 -.089 -.133
DIA .017 .229 .274 .451 -.489 -.136 -.259 -.424 -.349* -.304* .369 .361* .222 .206 .271 .329* -.089 1 .517
FD .264 .270 .243 .469 -.335* -.147 -.316* -.414 -.262 -.534 .119 .317* .182 .160 .194 .375 -.133 .517 1
AL = appetite loss; BI = body image; C = constipation; CF = cognitive functioning; D = dyspnoea; DIA = diarrhoea; DS = disease symptoms; EF = emotional functioning; F = fatigue; 
FD = financial difficulties; FP = future perspective; GHS = global health status; I = insomnia; NV = nausea/vomiting; P = pain; PF = physical functioning; RF = role functioning; SET = 
side effects of treatment; SF = social functioning; * Correlation is significant at the 0.05 level (2-tailed)
TABLE 6. Correlation between dimensions and scales in the EORTC QLQ-C30 and QLQ-MY20 (transplantation)
FP BI DS SET GHS PF RF EF CF SF F NV P D I AL C DIA FD
FP 1 .451** .029 .289 -.383 -.246 -.203 -.499 -,106 -.333* .287* .238 -.035 .145 .296* .371 .309* .049 .053
BI .451 1 -.142 .026 -.109 -.047 -.009 -.083 ,105 .016 .038 -.006 -.151 -.048 .333* .109 .053 -.029 -.195
DS .029 -.142 1 .447 -.312* -.589 -.449 -.339* ,228 -.397 .527 -.051 .707 .406 .145 .035 -.060 -.072 .188
SET .289 .026 .447 1 -.615 -.710 -.627 -.397 -,299 -.455 .570 .597 .519 .642   .377* .523 .470 .485 .337*
GHS -.383 -.109 -.312* -.615 1 .629 .518 .349* ,159 .498 -.436 -.467 -.423 -.443 -.071 -.192 -.429 -.371 -.370
PF -.246 -.047 -.589 -.710 .629 1 .562 .403 ,147 .506 -.645 -.375 -.643 -.447 -.379 -.325* -.232 -.171 -.443
RF -.203 -.009 -.449 -.627 .518 .562 1 .346* -,015 .580 -.563 -.341* -.626 -.403 -.194 -.200 -.209 -.127 -.421
EF -.499 -.083 -.339* -.397 .349* .403 .346* 1 ,188 .378 -.347* -.217 -.146 -.191 -.395 -.120 -.123 -.054 -.258
CF -.106 .105 .228 -.299 .159 .147 -.015 .188 1 .024 -.002 -.348* .023 -.041 -.105 -.033 -.304* -.143 -.250
SF -.333* .016 -.397 -.455 .498 .506 .580 .378 ,024 1 -.539 -.245 -.376 -.178 -.188 -.078 -.158 -.080 -.292*
F .287* .038 .527 .570 -.436 -.645 -.563 -.347* -,002 -.539 1 .299* .563 .294* .423 .441 .154 .266 .336*
NV 238 -.006 -.051 .597 -.467 -.375 -.341* -.217 -,348* -.245 .299* 1 .258 .263 .197 .587 .660 .464 .299*
P -.035 -.151 .707 .519 -.423 -.643 -.626 -.146 ,023 -.376 .563 .258 1 .563 .077 .182 .188 .143 .376
D .145 -.048 .406 .642 -.443 -.447 -.403 -.191 -,041 -.178 .294* .263 .563 1 .149 .346* .190 .356 .178
I .296* .333* .145 .377* -.071 -.379 -.194 -.395 -,105 -.188 .423 .197 .077 .149 1 .398 .123 .264 .288*
AL .371** .109 .035 .523 -.192 -.325* -.200 -.120 -,033 -.078 .441 .587 .182 .346* .398 1 .271 .363 .148
C .309* .053 -.060 .470 -.429 -.232 -.209 -.123 -,304* -.158 .154 .660 .188 .190 .123 .271 1 .540 .152
DIA .049 -.029 -.072 .485 -.371 -.171 -.127 -.054 -,143 -.080 .266 .464 .143 .356 .264 .363 .540 1 .104
FD .053 -.195 .188 .337* -.370 -.443 -.421 -.258 -,250 -.292* .336* .299* .376 .178 .288* .148 .152 .104 1
AL = appetite loss; BI = body image; C = constipation; CF = cognitive functioning; D = dyspnoea; DIA = diarrhoea; DS = disease symptoms; EF = emotional functioning; F = fatigue; 
FD = financial difficulties; FP = future perspective; GHS = global health status; I = insomnia; NV = nausea/vomiting; P = pain; PF = physical functioning; RF = role functioning; SET = 
side effects of treatment; SF = social functioning; * Correlation is significant at the 0.05 level (2-tailed)
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Medimurje. It is hard to define what is the predic-
tor for this result because one area is continental 
and the other is a coastal area. Both areas are devel-
oped and it could be that socio-economic circum-
stances in these areas have influenced the results. 
Development index is a composite indicator cal-
culated as a customized average of standardized 
values of socio-economic indicators for measur-
ing the degree of development in a given period. 
In Croatia, the following indicators are used to 
calculate the development index: average income 
per capita, average source income per capita, the 
average unemployment rate, movements of gen-
eral population, degree of education of the popula-
tion (tertiary education) and the aging index. Local 
self-government units are classified into categories 
considering development index. Third and fourth 
level represent above-average ranking units. Istria 
currently belongs to the forth level and Medimurje 
to the third level, which means that they are above-
average developed.26,27 For global health status 
the ranges are the lowest for respondents from 
Dalmatia. 
In addition, in this study we also aimed to as-
sess the impact of the disease and its primary sys-
temic treatment on their HrQoL in a prospective 
cohort of multiple myeloma patients older than 40 
years at the time of diagnosis. If we compare the 
results for general population and MM patients 
which were obtained using the EORTC QLQ-C30 
questionnaire, it can be seen that during the initial 
testing patients suffering from multiple myeloma 
have lower scores for global health status, physical 
functioning, role functioning and social function-
ing, while they have higher scores for fatigue, pain, 
appetite loss and financial difficulties. It can be 
concluded that they have more symptoms present. 
According to Delforge et al., about 70% of the 
patients suffer from pain at the time of diagnosis.28 
Our results indicate that pain is a great predictor of 
global health status in general population, as well 
as in MM patients. In general population, pain and 
fatigue were the most expressed symptoms, while 
in MM patients pain, fatigue, insomnia, dyspnoea 
and appetite loss were the most expressed symp-
toms. Severity, type of disease, symptoms and 
treatment are important determinants of HrQoL 
in patients with multiple myeloma. Advanced dis-
ease and treatment related symptoms are associ-
ated with lower HrQoL.16 
Our descriptive and exploratory analysis sug-
gests a beneficial effect of transplanted patients 
three months after therapy on HrQoL. HrQoL 
scores were higher among transplanted patients, 
compared to those who underwent chemotherapy. 
Respondents who underwent chemotherapy were 
mostly older than 70 years with a different co-
morbidity. They also indicate that approximately 
9 months passed from the occurrence of the first 
symptoms and diagnosis, due to the attribution of 
symptoms to other diseases, most commonly to spi-
nal diseases. Also, patients starting treatment for 
the first time are affected by the psychological bur-
den of their recent diagnosis and experience treat-
ment related toxicities which they have not previ-
ously been exposed to.29 Furthermore, the period 
of three months was sufficient for transplanted pa-
tients to recover from high doses of chemotherapy 
that preceded transplantation. On the other hand, 
patients who underwent chemotherapy, regardless 
of the small dosage of therapy, noticed that they 
have deterioration in symptoms.
The Netherlands study, also conducted on 51 
transplanted patients during the treatment and 12 
months after, shown that after 12 months the results 
were better for physical, role, emotional, cognitive 
and social functioning. Additionally, for symp-
toms, the results were better for fatigue, pain and 
appetite loss while nausea/vomiting and diarrhoea 
deteriorated in results.30 Our results illustrate that 
scores for global health status, physical function-
ing, role functioning and cognitive functioning are 
higher three months after transplantation, while 
results for fatigue, pain, dyspnoea and constipa-
tion are higher after chemotherapy. Patients who 
underwent chemotherapy had more symptoms 
present three months after therapy in comparison 
to patients who underwent transplantation. 
An additional valuable output from our study 
is the correlation analysis of the EORTC QLQ-C30 
scores and 4 items of the EORTC QLQ-MY20. This 
method can provide reliable, accurate descriptions 
of the HrQoL of patients with multiple myeloma.29 
Correlation analysis for patients on chemotherapy 
from our study shows that side effects of treat-
ment strongly correlate with body image and dis-
ease symptoms; furthermore, physical functioning 
strongly correlates with disease symptoms, side 
effects of treatment and role functioning, while 
emotional functioning correlates with side effects 
of treatment and social functioning. Cognitive 
functioning strongly correlates with disease symp-
toms, side effects of treatment and physical func-
tioning. When symptoms are taken into consid-
eration fatigue correlates with disease symptoms, 
side effects of treatment, physical functioning and 
cognitive functioning, while pain strongly corre-
lates with disease symptoms, physical functioning, 
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role functioning, cognitive functioning and fatigue. 
Appetite loss strongly correlates with disease 
symptoms, side effects of treatment, global health 
status, emotional functioning, social functioning, 
and nausea/vomiting.
Correlation analysis for transplanted patients 
from our study shows that global health status 
strongly correlates with side effects of treatment; 
furthermore, physical functioning strongly corre-
lates with disease symptoms, side effects of treat-
ment and global health status but also with role 
functioning; while role functioning and physi-
cal functioning correlate with social functioning. 
When symptoms are taken into consideration the 
pain strongly correlates with the largest number of 
items. Pain strongly correlates with disease symp-
toms, side effects of treatment, physical function-
ing, role functioning and fatigue. Other symptoms 
correlate only with one item as follows: dyspnoea 
with side effects of treatment, appetite loss with 
nausea/vomiting, constipation with nausea/vomit-
ing and diarrhoea with constipation.
The study conducted in France shows the 
strongest correlation between EORTC QLQ-C30 
global health status and QLQ-MY20 disease symp-
toms. They also highlight that information such as 
this may be useful in studies of HrQoL in multiple 
myeloma by helping to establish the factors that 
have greatest influence on the global health status 
score.29 These data do not represent the course of 
an individual patient’s disease. Nonetheless, they 
offer a basis for hypotheses regarding the factors 
that could influence HrQoL throughout the disease 
course.29 
Improvements in overall survival achieved in 
recent years with new therapies for MM patients 
are a great achievement. Data from clinical tri-
als suggest that the benefits of multiple myeloma 
treatment may outweigh the negative effects of 
toxicities and disease progression.29 Quality of life 
is influenced by the ability to adapt to unfortunate 
conditions or it can be said that that changes in 
HQL scores are subordinate to the individual sub-
jective assessment of life situations which they con-
sider to be important.31,32 However, the updating 
and improving QoL measure is essential to remain 
relevant in new treatments.33,34 Quality of life could 
be monitored objectively, excluding the impact of 
important socio-demographic factors.15 
In conclusion, this study is the first to present 
Croatian general population reference values for 
the EORTC QLQ-C30 questionnaire. Age, gender 
and place of residence are important predictors 
of quality of life in Croatian population. For MM 
patients, our study identified treatment effects 
consistent with those from other observational 
studies and provide new data on HrQoL across 
two different treatment choices for patients with 
multiple myeloma treated in Croatian clinical cen-
tres. According to available information there has 
been no research on MM patients before and after 
transplantation using the combination of EORTC 
QLQ-C30 and EORTC MY-20 questionnaires. It 
was recognized once again, that there is a need to 
compare the patient’s quality of life to the quality 
of life in the general population. 
Similarly as in the same research in our neigh-
bouring Slovenia,15 our results are applicable to 
more than 95% of the entire pool of Croatian can-
cer patients. Still, the HrQoL in Croatian general 
population could be further explored on larger 
sample sizes, and also with a wider range of age 
groups, where younger respondents could also 
be included. This might improve the applicability 
in patients that are diagnosed as children, adoles-
cents or young adults, especially given the socio-
demographic and political changes that have taken 
place in Croatia over the past 30 years.
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